Life Science Investing PharmaTher Closes Sale of Ketamine ANDA, Sharpening Focus on Long-Acting Injectable Ketamine Franchise
Life Science Investing PharmaTher Advances Strategy to Build Next-Generation Ketamine Franchise for Neuropsychiatric Disorders; Secures Exclusive Rights to Evaluate and License Patented Long-Acting Ketamine Program
Life Science Investing PharmaTher Applauds FDA's Commissioner's National Priority Voucher Selection of Ketamine; Company Highlights Potential Ketamine Opportunity, 505 Focus, and Upside from Strategic ANDA Sale
Life Science Investing PharmaTher Advances Phase 3 FDA Package for Ketamine in LID-Parkinson's Disease
Life Science Investing PharmaTher Announces KetAImine - AI Discovery Platform to Expand the Ketamine Portfolio, Enable Earlier Partnering, and Fast-Track 505 NDA Filings
Life Science Investing PharmaTher Provides Corporate Update on Ketamine Development and Commercial Strategy
Life Science Investing PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate over US$25 Million in Milestone and Profit-Sharing Payments
Life Science Investing PharmaTher Announces Sale of Ketamine ANDA with Potential to Generate Over US$25 Million in Milestone and Profit-Sharing Payments
Life Science Investing PharmaTher Advances Ketamine Patch as Non-Opioid Pain Relief Solution Leveraging FDA Approved IV Ketamine ), Aligned with FDA's CNPV National Priority Initiative
Life Science Investing PharmaTher Founder and CEO Issues Letter to Shareholders Following the FDA Approval of Ketamine )
